BR
BRTX.US BioRestorative Therapies Inc
- Market cap
- USD 2.06M
- P/E
- -
- P/B
- 0.68x
- ROE
- -284.8%
- Dividend yield
- 13.15%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is BRTX.US undervalued?
Graham numberThe Graham number of BioRestorative Therapies Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioRestorative Therapies Inc fundamental analysis
No fundamental analysis for BioRestorative Therapies Inc yet.
BioRestorative Therapies Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioRestorative Therapies Inc
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of p…
Full company profileBioRestorative Therapies Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioRestorative Therapies Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 36.4K | 81.0K | 111K | 130K | 77.0K | 46.0K | 120K | 146K | 401K | 360K | 92.7K |
| Gross Profit | 36.3K | -178K | 111K | - | 77.0K | 46.0K | 120K | 146K | 373K | 336K | 63.1K |
| Operating Income | -7.80M | -8.37M | -7.65M | -8.43M | -2.75M | -26.3M | -18.9M | -15.2M | -11.6M | -15.6M | -13.5M |
| EBITDA | -7.61M | -8.10M | -9.06M | -9.29M | -9.51M | -42.4M | -13.1M | -15.0M | -8.79M | -14.0M | -8.41M |
| Net Income | -8.64M | -9.44M | -12.5M | -14.6M | -11.3M | -44.3M | -13.2M | -10.4M | -8.98M | -14.2M | -8.62M |
| EPS | -169,339 | -138,892 | -131,766 | -753 | -571 | -746 | -73 | -49 | -23 | -32 | -9.72 |
| Balance Sheet | |||||||||||
| Total Assets | 1.58M | 1.76M | 1.19M | 1.47M | 4.35M | 22.5M | 16.4M | 12.6M | 12.3M | 4.08M | 4.64M |
| Total Liabilities | 6.58M | 8.60M | 9.83M | 14.2M | 5.68M | 856K | 6.14M | 2.61M | 3.75M | 3.72M | 1.61M |
| Shareholders' Equity | -5.00M | -6.84M | -8.64M | -12.8M | -1.33M | 21.6M | 10.3M | 10.0M | 8.53M | 357K | 3.03M |
| Cash & Short-term Investments | 31.8K | 452K | 118K | 1.66K | 3.06M | 21.0M | 14.7M | 11.1M | 10.7M | 2.95M | 3.59M |
| Total Debt | 2.16M | 3.66M | 4.15M | 7.75M | 4.79M | 671K | 302K | 162K | 162K | - | 34.5K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.00M | -3.85M | -5.10M | -6.92M | -1.96M | -3.33M | -5.91M | -6.43M | -8.23M | -10.8M | -15.2M |
| Capital Expenditure | 189K | 3.62K | 12.9K | 35.6K | 35.6K | 30.7K | 440K | 171K | 106K | 116K | 8.00 |
| Free Cash Flow | -5.19M | -3.86M | -5.12M | -6.95M | -1.96M | -3.36M | -6.35M | -6.60M | -8.34M | -10.9M | -15.2M |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | -205.1% | -128.5% | -104.1% | -105.3% | -3,992.2% | -284.8% |
| ROA | -546.6% | -537.1% | -1,049.8% | -999.0% | -259.3% | -197.3% | -80.5% | -82.6% | -73.1% | -349.1% | -185.7% |
| Net Profit Margin | -23,755.4% | -11,660.1% | -11,277.3% | -11,267.6% | -14,639.9% | -96,311.5% | -11,037.0% | -7,145.2% | -2,239.2% | -3,959.4% | -9,298.3% |
| Debt to Equity | - | - | - | - | - | 0.03x | 0.03x | 0.02x | 0.02x | - | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BioRestorative Therapies Inc dividends
- Dividend yield
- 13.15%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 271K | 0.60 | - |
| 2024 | USD 624K | 1.61 | - |
| 2023 | USD 569K | 2.70 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Sep 8, 2026.
Who owns BioRestorative Therapies Inc
- Insiders 6.22%
- Institutions 12.07%
- Public & others 81.71%
- Shares outstanding 1.38M
- Free float 1.21M
Top funds holding BRTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 6.33K | 0.46% | +0.02% | Sep 2026 |
| Fidelity Total Market Index | 671.00 | 0.05% | +0.15% | Sep 2026 |
| Fidelity Series Total Market Index | 428.00 | 0.03% | 0.00% | Sep 2026 |
Top institutions holding BRTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jane Street Group LLC | 804K | 2.91% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 711K | 2.57% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 287K | 1.04% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 273K | 0.99% | +14.54% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 181K | 0.66% | +359.55% | Jun 2026 |
| Geode Capital Management, LLC | 152K | 0.55% | -31.68% | Jun 2026 |
| Citigroup Inc | 63.7K | 0.23% | 0.00% | Jun 2026 |
| Wealth Alliance, LLC | 40.0K | 0.14% | 0.00% | Jun 2026 |
| State Street Corp | 32.5K | 0.12% | 0.00% | Jun 2026 |
| Keystone Financial Group Inc | 28.6K | 0.10% | 0.00% | Jun 2026 |
| Northern Trust Corp | 24.0K | 0.09% | 0.00% | Jun 2026 |
| Creative Planning Inc | 21.7K | 0.08% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 16.1K | 0.06% | 0.00% | Jun 2026 |
| StoneX Group Inc | 13.9K | 0.05% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 13.0K | 0.05% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 2.00K | 0.01% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 1.46K | 0.01% | +0.07% | Jun 2026 |
| SBI Securities Co Ltd | 699.00 | 0.00% | +251.26% | Jun 2026 |
| TD Waterhouse Canada Inc | 3.00 | 0.00% | 0.00% | Jun 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Jun 2026 |
BioRestorative Therapies Inc company profile
- Company name
- BioRestorative Therapies Inc
- Ticker
- BRTX.US
- Exchange
- USA Stocks
- Listed since
- Jul 27, 2007
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
- Fiscal year end
- December
- Address
- 40 Marcus Drive, Melville, NY, United States, 11747
- Phone
- 631 760 8100
- Website
- biorestorative.com
About BioRestorative Therapies Inc
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
BioRestorative Therapies Inc management
3- Mr. Mika GrassoInterim CEO & Director · born 1998
- Ms. Anna SkowronCFO & Treasurer · born 1987
- Ms. Crystal RomanoHead of Global Commercial Operations